primary

Survey from White Clay Finds Two-thirds of Customers Do Not Feel Truly Known by Their Primary Financial Institution

Data shows relationship gap between financial institutions and their customers is holding strong LOUISVILLE, Ky.--(BUSINESS WIRE)--White Clay, a leading provider…

23 hours ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025 07:00 ET  | Source: Sagimet Biosciences Inc. Denifanstat met all primary and secondary endpoints versus placebo and…

2 weeks ago

Light & Wonder Provides Delisting Notice to Nasdaq

LAS VEGAS--(BUSINESS WIRE)--Light & Wonder, Inc. (NASDAQ and ASX: LNW) (“Light & Wonder,” “L&W,” “we” or the “Company”) today provided…

2 weeks ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…

3 weeks ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…

3 weeks ago

Zarminali Pediatrics Welcomes New Chief Technology Officer to Advance Patient-Centric Connected Care Model

CHICAGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide elevated, seamlessly coordinated…

4 weeks ago

London School Joins Always Active Uniform Pilot to Combat Childrens Inactivity and Obesity Levels

Wednesday 1 October, 2025 Reception pupils at Harbinger Primary School received free movement friendly uniforms and activity bands to boost…

1 month ago

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

2 months ago

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…

2 months ago

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to…

2 months ago